President Biden’s prostate cancer has been confirmed as hormone-resistant — also known as castration-resistant prostate cancer (CRPC) — meaning it does not respond to hormone therapy, the first-line treatment for metastatic prostate cancer, according to confirmed reporting. This is clinically significant: it places Biden in the specific, more challenging category of prostate cancer in which first-line hormonal treatments have lost effectiveness, and newer targeted therapies become the primary treatment approach.
WHAT HORMONE-RESISTANT MEANS MEDICALLY
Prostate cancer typically depends on male hormones (androgens, primarily testosterone) to grow. The standard first-line treatment for metastatic prostate cancer is androgen deprivation therapy (ADT) — using medication or orchiectomy (surgical castration) to reduce testosterone levels to near-zero. Most prostate cancers respond initially to ADT; tumor growth slows or stops.
Castration-resistant prostate cancer (CRPC) is the stage where the cancer has developed mechanisms to grow even at castration-level testosterone. This happens because the cancer cells have adapted to proliferate with minimal androgen signaling, or because the cancer is producing its own androgens locally. CRPC is not treatable with ADT alone; it requires additional or alternative treatments.
THE TREATMENT OPTIONS FOR CRPC
Several therapeutic approaches are available for castration-resistant prostate cancer with bone metastases:
▸ Novel androgen receptor pathway inhibitors (ARPI): abiraterone (Zytiga), enzalutamide (Xtandi), apalutamide (Erleada), and darolutamide (Nubeqa) have extended median survival for CRPC patients significantly; these are typically the first additional treatment after castration resistance is confirmed
▸ PARP inhibitors: olaparib (Lynparza) and rucaparib (Rubraca) are approved for CRPC patients with specific DNA repair gene mutations (BRCA1/2); testing for these mutations is standard
▸ Immunotherapy: sipuleucel-T (Provenge) is an FDA-approved immune therapy for CRPC
▸ Chemotherapy: docetaxel and cabazitaxel are chemotherapy options for CRPC
▸ Radiopharmaceuticals: lutetium-177-PSMA (Pluvicto) targets a protein on prostate cancer cells and delivers localized radiation; highly effective in appropriate patients
At 83, Biden’s overall health and functional status will significantly influence which of these options are appropriate and tolerable. Modern CRPC treatment has substantially improved median survival — patients with CRPC who have access to sequential treatments are living years rather than months in many cases.
THE TRANSPARENCY NOTE
The hormone-resistant confirmation answers one of the five specific questions ONYX identified on August 16 as undisclosed. The remaining questions from that article: when was the cancer first detected; what monitoring occurred during the presidency; what is the specific extent of bone involvement; and what is the treatment plan. The disclosure has been partial: the hormone-resistant status is now confirmed; the timeline and monitoring questions remain unaddressed.
Hormone-resistant prostate cancer with bone metastases at 83. The treatment options are real and have extended median survival significantly. The prognosis is a personal medical matter. The transparency questions remain.
WHAT HAPPENS NEXT
▸ Treatment decision — Biden’s medical team will select from the CRPC treatment options; the selection will indicate the cancer’s specific characteristics and extent
▸ Disclosure — whether the remaining transparency questions (timeline, monitoring during presidency, bone involvement extent) are addressed
▸ Medical monitoring — CRPC treatment response is monitored through PSA levels, imaging, and clinical assessment
| CONFIDENCE: HIGH | Biden cancer hormone-resistant confirmation is from confirmed reporting. Medical analysis of CRPC (treatments, hormone pathway inhibitors, PARP inhibitors, etc.) is from established oncology literature. Transparency questions from August 16 ONYX documentation are from prior production. |
SOURCES
▸ Confirmed reporting — Biden prostate cancer hormone-resistant confirmation, August 23, 2026
▸ Oncology literature — castration-resistant prostate cancer treatment options (established)
Q: What is the prognosis for hormone-resistant prostate cancer with bone metastases?
A: Median survival for CRPC with bone metastases has improved significantly with modern treatments. Pre-modern treatment era: 12-18 months median survival. With sequential ARPI, chemotherapy, and radiopharmaceutical treatment: median survival has extended to 3-5+ years in clinical trials. At 83, Biden’s prognosis depends on his overall health, the cancer’s specific characteristics (which mutations are present), and his response to treatment. ONYX does not predict individual prognosis; these are population-level statistics that provide context.
Q: Is hormone-resistant cancer curable?
A: Metastatic CRPC is generally considered incurable with current treatments, though treatment has substantially extended survival. Some localized prostate cancers can be cured with surgery or radiation; metastatic CRPC that has spread to bones is managed rather than cured, with the goal of extending survival and maintaining quality of life.
Q: Why didn’t hormone therapy work?
A: Hormone-resistant prostate cancer typically develops after an initial period of hormone therapy response. Cancer cells that are not androgen-dependent survive and proliferate, eventually becoming the dominant cancer population. This is a normal disease progression pattern; it does not indicate treatment failure but rather disease evolution. Biden may have had a prior period of hormone-sensitive disease that progressed to hormone-resistant over time.
